57 results about "Axonchoides" patented technology

The invention discloses a functional polypeptide for promoting repair of endometrial stem cells to clitoris sensitive nerves and application, and belongs to the technical field of stem cell repair, the functional polypeptide is used for modifying the endometrial stem cells and Schwann cells through the functional polypeptide, and the clitoris sensitive nerves are repaired in a local slow-release gel delivery mode. The functional polypeptide can activate Laminin expression and regulate and control ECM degradation balance, so that collagen deposition in scar tissues is reduced; in addition, the functional polypeptide can effectively inhibit HOXA1 expression, enhance the axon extension capacity and strengthen the axon microtubulin polymerization capacity of the nerve injury part, and the nerve repair efficiency and the function recovery quality are remarkably improved.

Provided are: a novel compound that is useful for the treatment of diseases to be prevented, ameliorated, and / or treated by suppressing axon degeneration; and a pharmaceutical composition containing the same.　The present invention relates to: a compound represented by general formula (I) [in the formula, Ra, Rb, X1, R1, L1, L2, and R2 are as disclosed in the specification and as set forth in the claims] or a pharmaceutically acceptable salt thereof; and a pharmaceutical composition containing the same.

The invention relates to a multi-targeting nanogel drug and application thereof in relieving neuroinflammation and promoting spinal cord injury repair, the multi-targeting nanogel drug comprises quercetin-loaded liposome, the quercetin-loaded liposome comprises TAT peptide and CAQK peptide, the quercetin-loaded liposome is incorporated into double-network gel, and the double-network gel is used as a drug carrier. The dual-network gel is jointly formed by a dopamine grafted hyaluronic acid polymer and methacrylated gelatin. The multi-targeting nanogel drug can improve the dissolving property of quercetin, reduce toxic and side effects, promote targeting of an injured part, and contribute to passing through a blood spinal cord barrier, so that the integrity of the blood spinal cord barrier is protected, the spinal cord microenvironment is optimized, formation of glial scars is reduced, axon regeneration is promoted, and the recovery of a motor function is enhanced.

The invention discloses a drug-loaded polymer, an STAT3 inhibitor composite nanoparticle, a preparation method of the STAT3 inhibitor composite nanoparticle and application of the STAT3 inhibitor composite nanoparticle in ophthalmic drugs. The STAT3 inhibitor composite nanoparticle comprises the drug-loaded polymer, an STAT3 inhibitor loaded on the drug-loaded polymer and thermosensitive lipidosome. The drug-loaded polymer is astaxanthin macromolecules, and the astaxanthin macromolecules are prepared by the following steps: in an inert atmosphere, performing condensation polymerization on astaxanthin and HPMDA, and then performing end capping reaction by using mPEG-OH. The compound is used for treating retinal neuron progressive death and ophthalmic diseases caused by axon loss of the retinal neuron progressive death, can show good ROS response and consumption performance, inhibits necrotic apoptosis, apoptosis and pyroptosis of cells, relieves cell death performance, and can show good drug slow release performance.

To provide a method of treating an inflammatory neurological disease or condition that can result in destruction or degeneration of axons or myelin.SOLUTION: Provided is a combination comprising a) a compound of formula (I) or a pharmaceutically or veterinarily acceptable salt thereof; and b) one or more drugs selected from the group consisting of I) a compound of a particular formula or a pharmaceutically or veterinarily acceptable salt thereof; ii) a sphingosine-1-phosphate receptor inhibitor (S1PR modulator); and iii) a signal transducer and activator of transcription 3 (STAT3) inhibitor.SELECTED DRAWING: None

A neurite growth stimulant is a small molecule ENPP1 inhibitor. Small molecule ENPP1 inhibitors are capable of treating central nervous system (CNS) injury and promoting axonal regeneration. The ENPP1 inhibitor in the carrier can be administered at damaged nerves and their cell bodies to promote the regeneration of axons.

The present invention provides the use of the small molecule compound 2-D08 in the preparation of a drug for treating or preventing demyelinating diseases. As a small molecule compound, 2-D08 has a small molecular weight and is easily permeable through the blood-brain barrier to exert central pharmacodynamic effects. Moreover, the chemical synthesis method of 2-D08 is also very mature, which is conducive to reducing the preparation cost of drugs for treating demyelinating diseases, thereby alleviating the medical expenses of patients to a certain extent. 2-D08 can promote the regeneration of myelin sheaths of spinal cord axons, significantly improve the motor ability and nerve function recovery of mice, and is expected to become a disease-modifying treatment drug targeting the origin of brain damage in MS patients, with brain permeability and ion channel selectivity, and has very broad application prospects.

The invention relates to application of GMFB in preparation of a medicine for treating traumatic optic neuropathy. Research finds that on the third day of a rat ONC model, compared with normal control, GMFB expression is remarkably up-regulated; cholera toxin B subunit (Cholera Toxin Subunit B, CTB) tracing shows that the axons of a rat ONC model with the GMFB knocked out are remarkably lengthened (compared with those of a wild rat ONC model), and LFB (luxoLuxol Fast Blue) myelination staining shows that remyelination of the denatured axons can be effectively improved, axon regeneration is promoted, and the visual function is improved by knockout of the GMFB.

The invention discloses a macrophage-platelet targeting delivery system carrying genes and mitochondria as well as a preparation method and application of the macrophage-platelet targeting delivery system. The platelet loaded with the PPAR gamma gene nano-composite is covalently linked to the surface of macrophage through a click chemical reaction, and a novel cell composite carrier is constructed. According to the system, the natural chemotaxis of macrophages to an injured part is fully utilized to realize precise targeting, and PPAR gamma genes and functional mitochondria are synchronously released through platelet activation in an injured microenvironment, so that the energy metabolism and lipid homeostasis of the macrophages are cooperatively regulated and controlled, the cellular burial function of the macrophages is effectively recovered, and tissue repair and regeneration are promoted. Experimental results show that the delivery system is reliable in preparation method and high in targeting efficiency, axon regeneration, myelin sheath repair and motor function recovery can be remarkably promoted in a spinal cord injury model, and a brand-new synergistic treatment strategy is provided for tissue injury repair.

The present invention relates to novel substituted 1H-pyrazol-4-carboxamide compounds as SARM1 inhibitors, pharmaceutical compositions comprising the compounds, and methods of using the compounds and compositions to treat and prevent pathological conditions involving axial degeneration.

A method of interrupting sympathetic stimulation to the cardiovascular system of a patient in need thereof includes navigating a probe of a hand-held cryogenic therapy apparatus to a stellate ganglion or an autonomic tissue area peripheral to the stellate ganglion of the patient, the probe including a needle configured to produce a cooling zone for focused cryogenic therapy, aligning the needle with one or more desired nerves of the stellate ganglion or the autonomic tissue area peripheral to the stellate ganglion, and producing the cooling zone to provide cryogenic therapy to the desired nerves of the stellate ganglion or the autonomic tissue area peripheral to the stellate ganglion at a temperature sufficient to cause axonotmesis of the nerves.

The invention discloses a brush motor axon clearance testing device and detection and assembly equipment, the brush motor axon clearance testing device comprises an axon clearance testing mechanism and a jig assembly for a brush motor, the jig assembly is arranged below the axon clearance mechanism, and the brush motor axon clearance testing device is characterized in that the axon clearance testing mechanism comprises a testing installation stand column; an axon testing mechanism used for testing the axon position of the brush motor and a vacant position testing mechanism used for testing the vacant position of the brush motor are vertically arranged on the testing installation stand column in a sliding mode, the axon testing mechanism is vertically arranged on the stand column in a sliding mode, and the vacant position testing mechanism is fixedly installed on one side of the axon testing mechanism; the clearance testing mechanism comprises a clamping jaw assembly used for clamping the outer ring of the head of the magnetic ring of the brush motor and a flexible reset assembly which is connected with the clamping jaw assembly and is axially arranged.

The present invention relates to a nerve conduit including a hollow support including a spring-shaped engraved pattern formed on an inner wall and a biocompatible polymer fiber with a fiber direction aligned parallel to an axonal direction; and an electrically conductive hydrogel applied on the inside or outside of the hollow support, and a method of manufacturing the same.

The present invention relates to a novel injectable protein delivery system and a method for delivering one or more therapeutic agents to the central nervous system (CNS) to promote axonal regeneration. The system is based on the use of a recombinant spider silk protein, referred to as spiroin-SpyTag, which undergoes a rapid transition from a sol state to a gel state when exposed to ultrasonic treatment and incubated at body temperature. This unique characteristic allows the material to be easily injected into a specific target tissue. The methods disclosed herein can deliver a protein therapeutic agent covalently conjugated to spiroin-SpyTag to a subject affected by a CNS disorder or injury. In addition, methods of making such injectable protein delivery systems are fast, convenient, and economical and effective.

The present disclosure provides compounds and methods useful for inhibiting SARM1 and / or treating and / or preventing neurodegenerative disease or axonal degeneration. The provided SARM1 inhibitors may reduce or inhibit binding of NAD+ by SARM1. Alternatively, provided SARM1 inhibitors bind to SARM1 within a pocket comprising one or more catalytic residues (e.g., a catalytic cleft of SARM1).

The present invention provides an NSDP1 micropeptide and its application in repairing demyelinating damage, belonging to the field of biomedicine technology. The NSDP1 polypeptide of the present invention can significantly promote the remyelination of axonal demyelinating damage, providing a new idea and method for repairing nerve demyelinating damage.

The present disclosure relates generally to small molecule inhibitors of axonal degeneration or pharmaceutically acceptable salts, isotopically enriched analogs, stereoisomers, mixtures of stereoisomers, or prodrugs thereof, methods of making and intermediates thereof, and methods of using the same.

The present disclosure provides compounds and methods useful for inhibiting SARM1 and / or treating and / or preventing axonal degeneration. In some embodiments, the present disclosure provides certain compounds and / or compositions that are useful in medicine, and particularly for treating neurodegeneration (e.g., for reducing axonal degeneration). In some embodiments, the present disclosure provides compounds having a structure as set forth in Formula (I).

Embodiments of the instant disclosure relate to biomaterial for delivering extracellular vesicles derived from reactive cell populations for improving brain healing after injury. Also provided are methods of improving angiogenesis, axonogenesis, or inducing tissue repair using the disclosed biomaterials. Also provided are methods of making the biomaterials.

The subject invention pertains to a novel injectable protein delivery system and methods for delivering one or more therapeutic agents in the central nervous system (CNS) for promoting axon regeneration. This system is based on the use of a recombinant spider silk protein called spidroin-SpyTag, which undergoes a rapid transition from a sol state to a gel state when exposed to ultrasound treatment and incubated at body temperature. This unique characteristic allows the easy injection of the material into a specific target tissue. The methods herein disclosed allow the delivery of protein therapeutics covalently conjugated to the spidroin-SpyTag to a subject affected by a CNS disorder of injury. Additionally, the method for fabricating this injectable protein delivery system is rapid, convenient, and cost-efficient.

The application discloses a diagnostic marker detection system of a star-shaped glial cell IL-33 knockout EAE model, relates to the technical field of in vitro diagnosis, and comprises the following steps: constructing direction consistency constraint, four-domain prior weight and anchor point consistency scoring; selecting a minimum panel in four domains of inflammation chemotaxis, T cell subgroups, myelin axons and blood brain barrier, and generating Th17 / Th1 and MMP9 / closure protein ratio and chemotaxis combination; implementing standardized collection, platform alignment and bridge calibration, establishing intra-batch / between-batch quality control and time window limitation; performing learning with monotone constraint and two-stage calibration, and reserving animal-to-human population domain adaptation; and outputting star source index, double-threshold value stratification, longitudinal monitoring and interpretable report, so that cross-platform and cross-batch comparability, direction order preservation, traceability and clinical bridgeability are realized, and robust discrimination and reproducibility are improved.

The invention relates to a PFOS corticobrain organ injury model and a construction method and application thereof. The method comprises the following steps: (1) culturing corticobrain organs; (2) performing PFOS exposure on the cultured cortical brain organ to obtain a PFOS cortical brain organ injury model; (3) performing RNA-seq sequencing on the PFOS corticobrain organ injury model, and identifying whether the PFOS corticobrain organ injury model is successfully constructed or not through a molecular mechanism; the molecular mechanism comprises at least one of a P53signaling pathway and an axon guiding pathway, and the molecular mechanism comprises at least one of a P53signaling pathway and an axon guiding pathway; further, if the molecular mechanism appears, the PFOS cortical brain organ injury model is successfully constructed. The PFOS cortical brain organ injury model constructed by the method can promote deep research on PFOS injury brain pathological mechanisms, and a new perspective is provided for understanding the development process of diseases.